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ABSTRACT 
Objective: To compare the effects of treatment of acute pain in the emergency department using 
intravenous ketamine or intravenous morphine. Methods: A search was conducted in PubMed 
using the terms (“low dose ketamine” OR “sub-dissociative dose ketamine”) AND “morphine” 
AND (“emergency department” OR “ED”). The results were filtered for relevancy to our 
research question. Results: All three studies demonstrated similar effectiveness between 
morphine and ketamine in the first 30 minutes with similarly significant pain score reductions. 
However, the analgesic effects of morphine consistently lasted longer than ketamine, and less 
people in the morphine group required additional doses of medication. Adverse drug events 
occurred at similar rates between the groups; although, different side effect profiles were 
observed between the drugs, as expected. Conclusion: Ketamine does not appear to be a 
replacement for morphine; however, ketamine shows potential to be a safe and effective 
alternative option for treating acute pain in the ED. Further research is warranted to study the 
safety and efficacy low-dose ketamine at higher doses infused over a longer duration or as usage 
as an adjunct to morphine. 
 
INTRODUCTION 
Acute pain is the most common cause of emergency department (ED) visits in the United 
States.1 Patients presenting to the ED with moderate to severe pain are commonly treated with 
intravenous (IV) opioids. Morphine is mostly commonly used; however, a current shortage is 
creating a demand for other options.2,3 Other IV opioids available for treating acute pain, such as 
fentanyl and hydromorphone, are also in shortage according to the Food and Drug 
Administration (FDA).3  
 Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptors in the central 
nervous system and at higher doses may also bind to opioid mu and sigma receptors.4 Ketamine 
has been used as a dissociative general anesthetic for procedural sedation and intubation since 
the 1970s.5 Positive attributes of ketamine for acute pain management include a very large 
therapeutic window, rapid onset, and an adverse effect profile that is different from opioids.6,7 
Most importantly, ketamine has an absence of significant respiratory complications; however, 
elevated pulse and blood pressure, hallucinations, and dysphoria are common adverse effects.7  
 Low-dose IV ketamine is a potential candidate for safe and effective treatment of acute 
pain management in the ED. Using ketamine will help increase medication diversity, which will 
help prevent drug shortages by lessening the dependence on IV opioids. Using ketamine also 
gives an additional benefit of providing a non-opioid option for patients. This study aims to 
investigate ketamine as a safe and effective alternative to morphine for treatment of acute pain in 
the ED.  
 
PICO 
Population: Adult hospitalized patients with acute pain 
Intervention: IV Ketamine 
Comparison: IV Morphine 
Outcome: self-reported pain control and the occurrence of adverse reactions 
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CLINICAL QUESTION 
Can ketamine be used as a safe and effective alternative to morphine for the treatment of acute 
pain in the ED? 
 
METHODS 
As outlined in Figure 1, an initial search of PubMed was performed using the search 
terms (“low dose ketamine” OR “sub-dissociative dose ketamine”) AND “morphine” AND 
(“emergency department” OR “ED”). This database search yielded 27 articles, none of which 
were duplicates. We further screened these articles based on relevance to our study. For example, 
if the article did not mention the use of ketamine for managing acute pain it was excluded, which 
left us with 19 eligible articles. We then analyzed the remaining full-text articles to ensure they 
were an appropriate match for our study. Articles were excluded if they did not compare 
ketamine to morphine, if they focused on a single etiology of pain, or if they were meta-analyses. 
Ultimately, three randomized controlled trials were chosen to include in this study. These articles 
were chosen based on their comparison of morphine vs ketamine for treating acute pain, and 
their use of numeric rating scale (NRS) pain scales to measure outcomes (Appendix 1).  
  























 To compare the maximum change in NRS pain scores in patients receiving IV low-dose 
ketamine (LDK) or IV morphine (MOR) for acute pain in the emergency department.  
 
Study Design 
 The study was conducted in a tertiary, level one trauma center ED at San Antonio 
Military Medical Center, with a patient population of uniformed military personnel (20%) and 
civilians (80%). A convenience sample was obtained using standard enrollment protocol and 
patients were selected based on criteria defined in Table 1. 
Forty-five subjects were enrolled from March to November 2012 with similar 
demographic variables, vital signs, and baseline NRS (7.1) pain scores. Patients were randomly 
assigned to receive an initial dose of 0.3 mg/kg IV LDK (n=24) or 0.1 mg/kg IV MOR (n=21) 
infused over 5 minutes. After 20 minutes, the patient was asked if another dose was needed. This 
question was repeated every 20 minutes until 120 minutes had elapsed. Protocol allowed for a 
second, equal dosage to be given as early as 20 minutes post-initial dose. Data collection was 
stopped if the patient requested a third dose, underwent procedural sedations, or was discharged 
from the ED. Midazolam treatment was allowed for agitation or emergence reactions, and 
naloxone treatment was allowed for evidence of opioid overdose. Any other medication reactions 
were treated per the provider’s discretion.  
The primary outcome measurement was the maximum change on the verbal NRS pain 
score as compared to the baseline score. Clinically meaningful change in the NRS score from 
baseline was deemed to be 2 points between the treatment groups. The pain score was obtained 
prior to drug administration and after administration at 5, 10, 20 minutes and then every 20 
minutes thereafter up to 120 minutes. Secondary outcomes included levels of agitation or 
sedation as measured by the Richmond Agitation-Sedation Scale (RASS), vital signs, adverse 
events, and need for repeat dosing. Providers and nurses were surveyed after the patient 
encounter to rate their satisfaction with the medication on a scale of 1 (very dissatisfied) to 5 
(very satisfied). The outcomes were recorded and entered into a secured electronic database by a 















Table 1. Inclusion and exclusion criteria for participation in study 1. 
 
Inclusion Criteria Exclusion criteria  
18 to 59 years  
Acute abdominal, flank, low back, or 
extremity pain that the ED provider felt 
warranted IV opioid treatment 
Oxygen saturation < 95% 
Systolic blood pressure < 90 mmHg or > 180 
mmHg 
Pulse rate < 50 or > 120 beats/min 
Respiratory rate < 10 or > 30 respirations/min 
AMS 
Intoxication 
Fibromyalgia or other chronic pain condition 
requiring the use of opioids or tramadol as 
outpatient 
Ischemic heart disease, heart failure, or 
unstable dysrhythmias 
Use of an opioid or tramadol within 4 hours 
prior to enrollment 
Allergy to morphine or ketamine 
Required pain medication immediately 
Pregnant or breastfeeding 




Presence of intracranial mass 
History of psychosis 
Weight < 45 kg or > 115 kg 




The maximum change in NRS pain score from baseline in the MOR group was 5 at 100 
minutes and 4.9 in the LDK group at 5 minutes. In the LDK group, there was an initial decrease 
in pain scores followed by a rapid increase within the first 20 minutes, whereas the MOR group 
experienced a steady trend of reduced pain over time (Table 2). A second dose was administered 
in 54% of the ketamine group and only 38% in the morphine group. A third dose was requested 
in 25% of the ketamine group and 14% in the morphine arm.  
Secondary outcomes were similar between the groups. RASS scores varied within the 
first 20 minutes after drug administration in both groups, but subsequent variation from baseline 
was minimal. Ketamine caused a statistically significant increase in systolic blood pressure at 5 
and 10 minutes from the morphine group, but no other differences were observed in vital signs. 
Most notably, patients in the MOR group experienced more headache, drowsiness, and decreased 
oxygen saturation, whereas the LDK group experienced more dysphoria and hallucinations. 
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However, adverse event rates were similar across treatment groups. Neither Midazolam nor 
naloxone was administered during the study and there were no dissociation or emergency 
reactions.  
The median provider satisfaction score was 4 (somewhat satisfied) for both LDK and 
MOR groups, whereas the median nursing satisfaction score was 4 (somewhat satisfied) for LDK 
and 5 (very satisfied) for the MOR group.  
 
Table 2. Pain scores overtime in study 1. 
Time Morphine (95% CI) Low-dose ketamine (95% CI) 
T5 − 3 (− 3.9, − 2.1) − 4.9 (− 5.8, − 4) 
T10 − 3.4 (− 4.4, − 2.5) − 4.3 (− 5.5, − 3.1) 
T20 − 3.3 (− 4.4, − 2.2) − 3.2 (− 4.4, − 2.1) 
T40 − 4.5 (− 5.6, − 3.5) − 3.7 (− 5.2, − 2.3) 
T60 − 4.8 (− 5.8, − 3.8) − 3.5 (− 5.4, − 1.6) 
T80 − 4.4 (− 5.9, − 2.9) − 3.9 (− 6.1, − 1.6) 
T100 − 5 (− 6.6, − 3.5) − 4.1 (− 6.8, − 1.5) 




Strengths include the study design and similar group characteristics. The study directly 
compared morphine to ketamine for analgesia with a prospective, double-blinded randomized 
control trial. The sample population had similar demographic variables, vital signs, and baseline 
NRS pain scores, so confounding variables were limited.  
 The study had many limitations, such as small sample size with a possible 
generalizability limitation, a non-standardized dose of ketamine for analgesia, and the use of 
RASS in a non-validated setting. The sample size was approximately 20 patients per treatment 
group enrolled at a military medical center. Results of the study may not be generalizable due to 
the study location at a military medical center and sampling bias due to a convenience sample. 
Due to the small sample, statistical analysis had to detect a two-point difference in maximum 
change in NRS scores from baseline between the groups.  Other authors have reported 1.3 as a 
statistically significant change in NRS scores, so a greater difference in clinical effect between 
the groups may be observed in a larger sample.8 A standardized dose of ketamine for analgesia is 
not available, so the authors extrapolated data from other studies that suggested 0.3 mg/kg dosing 
for adequate pain control without adverse neurologic effects.9 The RASS was used to measure 
sedation and agitation. RASS is standardly used in the setting of the intensive care unit but not in 
the ED, so the reliability and validity of this scale has not been established in the sample 
population of this study. 
 
Study 2 
Acute pain management in emergency department, low dose ketamine versus morphine, a 
randomized clinical trial. Mahshidfar et al.7 
 
Objective 
 To compare analgesic effects of low dose ketamine versus morphine in trauma patients 
presenting to the ED. 




 A double-blinded randomized clinical trial was conducted in two university teaching 
hospital EDs in Tehran, Iran. Participants in this study were trauma patients aged 18 to 70 years 
old who were referred to the ED with a musculoskeletal pain score of at least 5 on a standard 
NRS. Other inclusion and exclusion criteria are summarized in Table 3. 
From September 2014 to September 2015, 332 eligible participants were enrolled, but 32 
patients were excluded from analysis due to study refusal, patient requesting morphine or 
ketamine only, incomplete data, or disrespect to the study protocol. There was minimal 
difference between the groups’ demographic characteristics, vital signs, or baseline pain scores. 
Participants were randomly assigned into IV LDK (0.2 mg/kg) or IV MOR (0.1 mg/kg) treatment 
groups equally using block randomization. Pain score, vital signs, and side effects were 
measured at 0, 15, 30, 45, and 60 minutes after the drug was administered. Adequate pain 
reduction was defined as a decrease in NRS pain score equal to 3 or more. If there was 
insufficient pain reduction, 3 mg of IV morphine was injected every 5 minutes as a rescue 
analgesic. Patient satisfaction was asked one hour after drug injection on a 5-point scale; a 
response of 4 or 5 were defined as reaching proper analgesic effect.  
 The primary outcome measured in this study was change in NRS pain score as compared 
to baseline over time. Other outcomes measured were changes in vital signs, development of 
adverse effects, and patient satisfaction. The medication was administered by a blinded nurse, 
but the study did not clearly state the outcome recorder.   
 
Table 3. Inclusion and exclusion criteria for participation in study 2. 
 
Inclusion Criteria Exclusion Criteria 
18 to 70 years old 
Trauma patients presenting to ED 
Rated pain at 5 or more on standard 0-10 NRS 
Unstable vital signs 
Head trauma 
Glasgow coma scale < 15 
Opiate user 
Psychiatric or cardiac problem 
Hypersensitivity to ketamine or morphine 
Pregnancy 
Breastfeeding 
Renal or hepatic insufficiency 
Upper respiratory infection 
Patient requesting morphine or ketamine only 
 
Study Results  
The average baseline NRS pain score was 8.1 in the ketamine group and 8.4 in the 
morphine group. There was a statistically significant reduction in pain scores at 15 minutes in 
both groups with no significant difference between the groups. Subsequently at 30, 45, and 60 
minutes, the morphine group had statistically significant lower pain scores than the ketamine 
group (Table 4).  
 No life-threatening adverse effects were observed in either group. The morphine group 
experienced a statistically significant higher incidence of flushing and decreased oxygen 
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saturation below 90%. Other minor adverse effects were observed with equal incidence between 
the groups such as nausea, dizziness, and mood changes. A higher score rate of patient 
satisfaction was reported in the morphine group one hour after administration.  
 
Table 4. Pain trends overtime in study 2.  




0 8.1±1.1 8.4±0.9 0.15 
15 4.1±2.8 4.0±2.5 0.23 
30 4.5±3.1 3.8±3.0 0.01* 
45 4.8±3.2 3.4±3.1 < 0.001* 
60 4.9±3.3 3.2±2.9 < 0.001* 
*P Values with statistical significance.  
 
Study Critique 
  Strengths include the design, large sample size, and similar group demographics. The 
study directly compared morphine to ketamine for analgesia with a double-blinded, randomized 
controlled trial. This study has a large sample size since patients were enrolled from two large 
teaching hospitals. Confounding variables were reduced due to similar patient demographics 
between the groups.   
Alternatively, limitations of the study were a potential for unblinding and limited 
generalizability. There was a potential for unblinding due to the specific adverse reactions 
associated with each medication. Extrapolation of the results to patients in the United States may 
be problematic due to cultural or medical practice differences in Iran.  
Study 3 
Intravenous subdissociative-dose ketamine versus morphine for analgesia in the emergency 
department: A randomized controlled trial. Motov et al.10 
 
Objective 
To compare the analgesic efficacy and safety of IV subdissociative-dose ketamine versus 
morphine for acute pain in ED patients. 
 
Study Design 
The study was conducted in a 711-bed community teaching hospital as a prospective, 
double-blinded, randomized control trial. Participants were 18 to 55 years old who presented to 
the ED with acute abdominal, flank, back, or musculoskeletal pain rated at least 5 on a standard 
NRS. Other inclusion and exclusion criteria are summarized in Table 5.  
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Between June 2013 to May 2014, 90 participants were enrolled through convenience 
sampling. The groups were similar regarding demographic characteristics, baseline vital signs, 
pain scores, and chief complaint. Block randomization was utilized to equally divide participants 
into treatment groups IV MOR (0.1 mg/kg) or IV LDK (0.3 mg/kg). Pain scores, vital signs, and 
adverse effects were recorded at 15, 30, 60, 90, and 120 minutes after drug administration. If the 
patient reported a pain NRS score of 5 or more and requested additional pain relief, 1 µg/kg of 
fentanyl was utilized for rescue analgesia. 
The primary outcome was comparative NRS pain score reduction after 30 minutes 
between the treatment groups. Clinically meaningful change in the NRS score of acute pain in 
the ED was deemed to be 1.3 between the treatment groups as evidenced by other studies.8 Other 
outcomes analyzed were fentanyl rescue at 30 or 60 minutes, vital signs, and adverse reactions. 
Outcomes were measured by a blinded provider then recorded by the blinded data-collection 
team. The ED pharmacist, research manager, and statistician were not blinded. 
 
 
Table 5. Inclusion and exclusion criteria for participation in study 3. 
Inclusion Criteria Exclusion Criteria 
18 to 55 years old 
Presenting to Ed with acute (onset within 7 days) abdominal, 
back, flank, or musculoskeletal pain 
Rated pain a score of 5 or more on standard 0-10 NRS 
Attending physician determined opioid analgesia is needed 
Pregnancy 
Breastfeeding 
Altered mental status 
Allergy to morphine or 
ketamine 
Weight < 46 kg or > 115 kg 
Systolic blood pressure < 90 or 
> 180 mmHg 
Heart rate < 50 or > 150 bpm 
Respiratory rate < 10 or > 30 
bpm 
History of acute head or eye 
injury 
History of seizure 
History of intracranial 
hypertension 
History of chronic pain 
History of hepatic or renal 
insufficiency 
History of alcohol or drug 
abuse 
History of psychiatric illness 
Opioid use within last 4 hours 
 
Study Results 
Patients in both groups showed significant reductions in NRS pain scores at 15 minutes (-
1.0) and 30 minutes (0.2), but no statistically significant difference was detected between the 
groups. The changes in NRS pain scores for each group from baseline to 30 minutes showed a 
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similar pattern of decline. More patients in the ketamine group experienced a complete resolution 
of pain (NRS=0) at 15 minutes than patients in the morphine group; however, the difference had 
dissipated at the 30-minute mark (Table 6). There was no statistically significant difference in 
the use of rescue fentanyl at 30 and 60 minutes between the groups, but the ketamine group 
required significantly more rescue fentanyl at the 120-minute mark.  
 No serious or life-threatening adverse events occurred with either medication. More 
patients in the ketamine group reported minor adverse effects immediately after medication 
administration and at the 15-minute mark when compared to the morphine group, but the 
difference equalized at the 30 minutes. The most common minor adverse effects reported in both 
groups were dizziness and nausea. Neither group experienced any significant change to vital 
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Table 6. Pain trends overtime in study 3.10 
 




Strengths include design, study location, and similar group demographics. The study 
directly compared morphine to ketamine for analgesia with a double-blinded, randomized control 
trial. The sample population was selected at a large community teaching hospital with a highly 
utilized ED, so the sample is potentially diverse. Confounding variables were reduced since the 
groups were similar regarding demographic characteristics and baseline vital signs, pain scores, 
and chief complaint. 
Alternatively, some weaknesses were small sample size, the use of convenience 
sampling, and participant inclusion was partially subjective. The use of convenience sampling 
can allow for sampling bias, so the sample may not be representative of the entire population. 
Inclusion was determined in part by the on-duty, attending physician’s subjective opinion on the 
patient’s need for opioid analgesia. 
 
DISCUSSION 
Acute, moderate to severe pain in the ED is most commonly managed with IV opioids. 
However, a current shortage of IV opioids is creating a demand for other options. Ketamine has 
been used as a dissociative general anesthetic since the 1970s and current research has been 
focused on ketamine utilization for safe and effective acute pain management.  
An overview of the three studies is provided (Table 7). The Miller et al and Motov et al 
studies are similar with small sample populations, similar pain characteristics, and the same drug 
dosage. Mahshidfar et al had the advantage of a large population size, although the patient 
population was trauma patients outside of the United States. All three studies used the NRS for 
quantifying pain scores and utilized double-blinding procedure.  
 
Table 7. Overview of studies 
 Miller, et al Mahshidfar, et al Motov, et al  
Patients, n  45 332 90 
Population 18-59 year olds  
Acute abdominal, 
flank, low back, or 
extremity pain 
18-70 year olds  
Trauma patients 
18-55 year olds  
Acute abdominal, 
back, flank, or 
musculoskeletal pain 
Location Military level 1 
trauma center ED. 
Uniformed military 
(20%) and civilians 
(80%) 
2 university teaching 
hospital EDs in 
Tehran, Iran 
711-bed community 
teaching hospital ED 
Primary interest Maximum change in 
NRS pain score as 
compared to baseline 
Change in NRS pain 
scores from baseline 
over time 
NRS pain score 
reduction after 30 
minutes  
Dosages 0.3 mg/kg LDK, IV 
0.1 mg/kg MOR, IV 
0.2 mg/kg LDK, IV 
0.1 mg/kg MOR, IV 
0.3 mg/kg LDK, IV 
0.1 mg/kg MOR, IV  
Blinding Yes Yes Yes 
Other outcomes 
measured 
Adverse events, vital 
signs, & provider 
satisfaction 
Adverse events, vital 
signs, & patient 
satisfaction 
Adverse events, vital 
signs, & fentanyl 
rescue  
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The primary outcome of the studies was pain reduction in ketamine versus morphine. All 
three studies showed effective pain relief in the first 20 minutes without a statistically significant 
difference between the treatment groups. The LDK group demonstrated an initial decrease in 
pain scores followed by an increase after 30 minutes, whereas the MOR group showed a steady 
decline in pain scores over time (Table 8). Specifically, in the Miller et al study, the maximum 
reduction in pain score for the LDK group was seen immediately after infusion completion and 
was sustained for only 5 to 10 minutes. In the MOR group, a steady decline in pain scores was 
seen with a maximum reduction reached at 100 minutes post-infusion.  
The short duration of ketamine’s analgesic effect likely led to the increased rate of 
subsequent doses in the Miller et al and Mahshidfar et al studies and increased rescue fentanyl 
use at 120 minutes in the Motov et al study. Miller et al observed repeat dosing for LDK (54%) 
versus MOR (38%) although the difference was not statistically significant. In the ketamine 
group, 25% of the patients did not complete the entire 120 minutes of data collection due to 
requesting a third dose versus the 14% of patients excluded in the morphine arm due to 
requesting a third dose. Mahshidfar et al study revealed a statistically significant difference 
between the groups requesting an additional dose of analgesia, 34% in the ketamine group and 
10% in the MOR group. Motov et al showed no statistically significant difference in the use of 
rescue fentanyl at 30 and 60 minutes between the groups, but the ketamine group required 
significantly more rescue fentanyl at the 120-minute mark (17% difference).  
 
Table 8. Overview of pain scores over time   
 Baseline T5 T10 T15 T20 T30 T60 T100 T120 
Miller et al          
Ketamine 7.13 2.23 2.83 - 3.93 - 3.63 3.03 3.53 
Morphine 7.14 4.14 3.74 - 3.84 - 2.34 2.14 2.14 
Mahshidfar et al          
Ketamine 8.1 - - 4.1 - 4.5 4.9 - - 
Morphine 8.4 - - 4.0 - 3.8 3.2 - - 
Motov et al          
Ketamine 8.6 - - 3.2 - 4.1 4.8 - 3.9 
Morphine 8.5 - - 4.2 - 3.9 3.4 - 3.7 
- Indicates that pain scores were not recorded at this time.  
 
 Secondary outcomes measured included adverse drug events, vital signs, and provider or 
patient satisfaction. No serious or life-threatening side effects were observed in any of the 
studies. All three studies showed no significant difference between the groups in the rate of 
minor adverse events, such as nausea and dizziness (Table 9).  Miller et al and Mahshidfar et al 
showed the MOR group experienced a statistically significant decrease in oxygen saturation. 
Miller et al also revealed the LDK group experienced more dysphoria and hallucinations. Motov 
et al observed a statistically significant increase in adverse effects immediately post-injection and 
at the 15-minute mark in the LDK group, but the difference between the groups equalized at 30 
minutes.  
 Miller et al found both drugs scored similarly with providers and nurses. The median 
nursing satisfaction score was 4 (somewhat satisfied) for LDK and 5 (very satisfied) for MOR, 
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but the difference was not statistically significant. Mahshidfar et al showed a greater patient 
satisfaction score in the morphine group one-hour post-injection.   
 





Dysphoria Hallucinations Flushing Nausea Dizziness 
Miller et al       
Ketamine 0 16% 13% - 13% 8% 
Morphine 5% 0 0 - 10% 5% 
Mahshidfar 
et al 
      
Ketamine 4% 4% - 0 16% 34% 
Morphine 18% 2% - 36% 17% 32% 
Motov et al       
Ketamine - 2% - - 13% 18% 
Morphine - 0 - - 20% 13% 
- Indicates that the adverse drug reaction was not analyzed. 
 
CONCLUSION 
In the treatment of acute pain, IV ketamine and IV morphine have a significant short-
term (15-30 minutes) reduction in pain scores; however, the effects of ketamine are 
unsustainable without repeat dosing after 30 minutes. Morphine maintains a longer duration of 
action without repeat dosing. Based on these results, ketamine does not appear to be an adequate 
replacement for morphine in the management of acute pain in the ED.   
Ketamine is still a promising alternative due to its similar short-term efficacy and safety 
profile.  It may be utilized in opioid-tolerant patients and in areas of IV opioid shortage. Since 
ketamine is unable to sustain pain relief over the normal course of an ED stay, further research is 
warranted for either higher doses of low-dose ketamine infused over a longer duration or the use 
of adjunctive medications for ED management of acute pain.   
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Appendix 1: Example of a normal rating scale (NRS) pain score chart.11  
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